RxDoctor Payments Data

James Frecka, MD

Internal Medicine · Cincinnati, OHNPI 1497719199

Payments from drug & device makers

$2,377in general payments, 2019–2025

Across 39 payments — averaging $60.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$2K
  • AstraZeneca$117
  • AbbVie$69
  • Amgen$51
  • Amarin Pharma, Inc.$47
  • Novo Nordisk$45
  • plus $213 from 9 others

What the payments were for

  • Speaking & faculty fees$1,78875%
  • Food & beverage$58925%

General payments by program year

19
20
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,377 in reported general payments places this provider in the 80th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$44,982
Medicare patients
213
Services billed
837

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide51$57,768
TrulicityDulaglutide41$52,546
MounjaroTirzepatide43$50,141
EliquisApixaban52$41,338
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr16$15,106
Breo ElliptaFluticasone/Vilanterol22$10,904
Repatha SureclickEvolocumab12$6,727
Lantus SolostarInsulin Glargine,hum.Rec.Anlog36$5,577
Combivent RespimatIpratropium/Albuterol Sulfate11$5,152
Gabapentin210$4,188
LantusInsulin Glargine,hum.Rec.Anlog32$3,787
Atorvastatin Calcium492$3,527
Metaxalone13$3,094
Valsartan129$2,925
Albuterol Sulfate HfaAlbuterol Sulfate86$2,346

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$35$102,68784 claims
Novo NordiskOzempic$45$57,76851 claims
PfizerEliquis, Paxlovid$1,835$42,76772 claims
GSKAnoro Ellipta, Breo Ellipta$16$26,01138 claims
Sanofi-aventis U.S. LLCLantus$12$3,78732 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →